Xlife Sciences AG Updates on Key Transactions and NASDAQ Plans

Zurich-based Xlife Sciences AG has announced significant updates concerning its partnerships and market listings. The company has disclosed its collaboration with Grupo Landsteiner, identifying twelve project companies that will join forces. These include technology platform firms like Inventum Genetics GmbH and biotechnology companies such as alytas therapeutics GmbH. This partnership aims to enhance scalability by combining innovative portfolios with industrial expertise, setting a framework for a NASDAQ listing in 2026.

Additionally, VERAXA Biotech AG has resolved all issues with regulatory bodies and plans to hold an extraordinary general meeting in January 2026. The VERAXA team is gearing up for active participation in the upcoming JP Morgan Health Care Conference in San Francisco.

Oliver R. Baumann, CEO of Xlife Sciences, acknowledges these developments as pivotal milestones. The transactions are expected to bolster the involved project companies without significant operational changes, leveraging Grupo Landsteiner's international reach.